000176750 001__ 176750
000176750 005__ 20180913061238.0
000176750 0247_ $$2doi$$a10.1111/j.1582-4934.2011.01440.x
000176750 022__ $$a1582-4934
000176750 02470 $$2ISI$$a000305791600019
000176750 037__ $$aARTICLE
000176750 041__ $$aeng
000176750 245__ $$aAngiostatic kinase inhibitors to sustain photodynamic angio-occlusion
000176750 269__ $$a2012
000176750 260__ $$c2012
000176750 336__ $$aJournal Articles
000176750 520__ $$aTargeted angiostatic therapy receives major attention for the treatment of cancer and exudative age-related macular degeneration (AMD). Photodynamic therapy (PDT) has been used as an effective clinical approach for these diseases. Since PDT can cause an angiogenic response in the treated tissue, combination of PDT with anti-angiogenic compounds should lead to improved therapy. The current study was undertaken to test the clinically used small molecule kinase inhibitors Nexavar(®) (sorafenib), Tarceva(®) (erlotinib), and Sutent(®) (sunitinib) for this purpose, and compare the results to the combination of Visudyne(®)-PDT with Avastin(®) (bevacizumab) treatment. When topically applied to the chicken chorioallantoic membrane (CAM) at embryo development day (EDD) 7, a clear inhibition of blood vessel development was observed, with sorafenib being most efficient. To investigate combination with phototherapy, Visudyne(®)-PDT was first applied on EDD11 to close all <100 μm vessels. Application of angiostatics after PDT resulted in a significant decrease in vessel regrowth in terms of reduced vessel density and number of branching points/mm(2). While for all compounds the 50% effective dose (ED(50)) was approximately 10-fold lower, sorafenib also outperformed the other compounds. In vitro, all kinase inhibitors decreased the viability of human umbilical vein endothelial cells (HUVEC). Sunitinib convincingly inhibited the in vitro migration of endothelial cells. These results suggest the therapeutic potential of these compounds for application in combination with PDT in anti-cancer approaches, and possibly also in the treatment of other diseases where angiogenesis plays an important role.
000176750 6531_ $$aanti-angiogenic
000176750 6531_ $$abevacizumab
000176750 6531_ $$aCAM model
000176750 6531_ $$aImageJ
000176750 6531_ $$akinase inhibitor
000176750 6531_ $$aphotodynamic therapy
000176750 6531_ $$aRenal-Cell Carcinoma
000176750 6531_ $$aMacular Degeneration
000176750 6531_ $$aCombination Therapy
000176750 6531_ $$aTumor Angiogenesis
000176750 6531_ $$aTargeted Therapies
000176750 6531_ $$aGene-Expression
000176750 6531_ $$aCam Model
000176750 6531_ $$aPhase-Ii
000176750 6531_ $$aIn-Vivo
000176750 6531_ $$aVerteporfin
000176750 700__ $$0245027$$aNowak-Sliwinska, Patrycja$$g168504
000176750 700__ $$0245759$$aWeiss, Andrea$$g191745
000176750 700__ $$avan Beijnum, Judy R.
000176750 700__ $$aWong, Tse J.
000176750 700__ $$aBallini, Jean-Pierre
000176750 700__ $$0240637$$aLovisa, Blaise$$g171247
000176750 700__ $$0240886$$avan den Bergh, Hubert$$g106613
000176750 700__ $$aGriffioen, Arjan W.
000176750 773__ $$j16$$k7$$q1553–1562,$$tJournal of cellular and molecular medicine
000176750 909C0 $$0252359$$pGR-VDB
000176750 909C0 $$0252376$$pLPAS
000176750 909CO $$ooai:infoscience.tind.io:176750$$pSB$$pSTI$$particle
000176750 917Z8 $$x171247
000176750 917Z8 $$x148230
000176750 937__ $$aEPFL-ARTICLE-176750
000176750 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000176750 980__ $$aARTICLE